UK-India Free Trade Agreement: A Risk to Affordable Medicines

In the heart of New Delhi, bustling with energy, a healthcare crisis simmers beneath the surface. Residents crowd the corridors of government hospitals, where long lines often translate to prolonged suffering. For many, access to affordable medicines is not just a matter of health—it’s a matter of survival. Recent revelations surrounding the UK-India Free Trade Agreement (FTA) deepen this crisis, raising alarms among experts about the potential erosion of public health safeguards that have long protected Indian citizens.

A Shift in the Balance of Power

The latest discussions of the UK-India Free Trade Agreement have revealed provisions that tilt the balance heavily in favor of patent rights holders, a move that could have debilitating consequences for access to affordable medicines in India. Experts assert that the agreement leans towards satisfying the demands of developed nations, systematically undermining the public interest safeguards embedded in the Indian Patents Act.

Biswajit Dhar, an international trade expert, expressed grave concern over one critical aspect of the negotiations: “The explicit preference on voluntary licenses leaves access to medicines in the hands of market forces, undermining the government’s role in ensuring affordability for its citizens.” This sentiment underscores the stark realities faced by those dependent on affordable treatments—who will be left vulnerable in the wake of corporate interests.

The Potential for Public Health Compromise

The provisions in the comprehensive economic and trade agreement (CETA) highlight a concerning focus on TRIPS (Trade-Related Aspects of Intellectual Property Rights) and public health measures. This orientation effectively transforms voluntary licensing into the preferred route for promoting access to medicines, a choice that diminishes the impact of compulsory licenses, traditionally a tool for addressing public health emergencies.

• Voluntary Licenses: Dependent on market forces, potentially increasing costs.
• Compulsory Licenses: Essential during health emergencies but curbed by new FTA provisions.
• Public Health Safeguards: Historically protected in Indian law but threatened now.

Jyotsna Singh, co-convener of the Working Group on Access to Medicines and Treatments, echoes these concerns: “Such provisions effectively compromise the ability of potential compulsory license applicants to prove unmet demands, which are necessary grounds for accessing life-saving medications.” This alarming development could empower pharmaceutical corporations to evade accountability, masking the issue of exorbitant pricing as they retreat behind layers of legal jargon.

The Implications for Indian Legislation

The agreement’s language could further entrench the notion of patent harmonization—wherein patents granted in other countries would automatically apply in India. K M Gopakumar, another advocate within the Working Group, explains the gravity of this shift: “Harmonization means India may apply less scrutiny than it currently does. Our existing provisions prevent evergreening, the practice of granting patents on minor tweaks of existing medicines, but that will be jeopardized.”

Impact on Access and Technology

Think tank GTRI has raised the alarm, asserting that India has conceded crucial elements regarding compulsory licenses, potentially depriving the country of vital tools for accessing life-saving technologies during emergencies. These emerging realities reveal a stark choice: opt for corporate compliance or safeguard citizen rights to health. Further complicating this landscape, the agreement introduces “adequate remuneration” norms for compulsory licensing in the pharmaceutical sector, posing risks of delaying future access to both affordable medicines and green technologies.

Data from a recent study suggests that nearly 70% of low-income families in India are already struggling to afford essential medications, a statistic that will likely worsen if current provisions in the FTA go unchecked. “These negotiations are a dire warning of how external pressures can erode health sovereignty,” cautioned another expert, Dr. Reema Mehta, a public health researcher with an advocacy background.

A Call to Action

As the stakes grow ever higher amidst these negotiations, the implications for India’s public health system loom large. The delicate fabric of healthcare access is at risk of unraveling, propelled by an evolving landscape that increasingly prioritizes corporate interests over citizen welfare. The urgency for civil society organizations and policymakers cannot be overstated—initiatives to advocate for changes that solidify public health interests must intensify.

Within the corridors of power, deliberations may seem abstract, but for the countless Indians reliant on affordable healthcare, the outcomes hold life-altering significance. As discussions about the UK-India Free Trade Agreement progress, the question remains: Will India stand firm to protect its people, or will it cede sovereignty to corporate entities whose motivations may not align with public welfare?

Source: www.theweek.in